Abstract:e15087 Background: Desmopressin (dDAVP) is a hemostatic drug that acts as an agonist of the arginine vasopressin receptor 2 (AVPR2) that is present in vascular and malignant cells. Preclinical data show that dDAVP triggers cytostatic mechanisms, blocking angiogenesis and reducing metastases by limiting the survival of circulating tumor cells. Triple-negative breast cancer (TNBC) is associated with poor prognosis due to limited response to therapy and frequent early metastatic recurrence. Considering the unsatisfied clinical need for novel therapeutic options in TNBC, we evaluated the antitumoral activity of dDAVP on experimental models of TNBC, alone or in addition to chemotherapy. We also assessed the expression and clinical impact of AVPR2 in breast cancer samples. Methods: Human and murine TNBC cell lines were used for in vitro experiments. Target expression was assessed by qPCR and immunohistochemistry (IHC), in experimental or clinical tumors (NCT01606072). Effects of dDAVP were evaluated by proliferation, clonogenic, 3D growth and chemotaxis assays, qPCR arrays, and confocal microscopy. Local and distant tumor progression were assessed in vivo in nude or BALB/c mice. TIMER2.0 and UCSC Xena platforms (BRCA TCGA /n = 1260) were used for bioinformatic studies. Results: dDAVP significantly reduced growth and chemotaxis of AVPR2-expressing TNBC cells. Cytostatic effects of dDAVP were associated with altered actin cytoskeleton dynamics and differential expression of angiogenesis and metastasis-related genes. Cooperative effects were observed in vitro and in vivo after combining dDAVP with taxane or alkylating therapy. Tumor-bearing mice were treated with intravenous injections of dDAVP (0.3 μg/kg, thrice weekly) in combination with weekly cycles of paclitaxel (10 mg/kg i.p.) or carmustine (25 mg/kg i.p.). Combination regimens resulted in greater survival and tumor growth and metastasis inhibition. Bioinformatic analysis of the TCGA database showed that AVPR2 had a positive prognostic impact on overall survival in breast cancer patients, especially in the basal-like molecular subtype. AVPR2 also correlated with different immune cell infiltrates such as NK and dendritic cells, and CD4+ and CD8+ T cells. Moreover, AVPR2 expression was detected by IHC in 6/18 breast cancer clinical samples using a small cohort of surgical specimens. Conclusions: AVPR2 expression is associated with improved outcomes in patients with TNBC. Agonist activation of AVPR2 using dDAVP leads to cancer cell growth inhibition in TNBC cell lines and mouse models. We propose dDAVP as a potential novel therapeutic option for treating TNBC either as monotherapy or in combination with chemotherapy. The therapeutic impact of its addition to immune checkpoint inhibitors remains to be explored.

Role of desmopressin in reducing blood loss following breast cancer radical operation

Blood Conservation Strategies in Cardiac Valve Replacement

Perioperative Intervention to Prevent Lower Extremity Deep Venous Thrombosis after Gynecologic Surgery

Effect of Preoperative Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss Control in Patients Undergoing Cesarean Delivery: a Systematic Review and Meta-Analysis

Blood conservation strategies in cardiac valve replacement: A retrospective analysis of 1645 patients.

Desmopressin to reduce periprocedural bleeding and transfusion: a systematic review and meta-analysis

Clinical Effect of Desmopressin on Local Hemostasis After the Operation of Mixed Hemorrhoids

Preventing the Complication of Post-modified Radical Operation on Breast Cancer with REDON Drainage(affiliated 282 cases of investigation)

Effect of desmopressin administration on intraoperative blood loss and quality of the surgical field during functional endoscopic sinus surgery: a randomized, clinical trial

Safety and efficacy of desmopressin (DDAVP) in preventing hematoma expansion in intracranial hemorrhage associated with antiplatelet drugs use: A systematic review and metaanalysis

Control of Retropubic Dorsal Vein Complex during Laparoscopic Radical Prostatectomy

Repurposing hemostatic drug desmopressin in AVPR2-expressing triple-negative breast cancer: Target expression analysis and preclinical antineoplastic effects on tumor growth and metastatic progression.

Continous Subcutanceous Sewing and REDON Absorbing Bottle Drainage in Modified Radical Mastectomv for Breast Cancer

Tranexamic acid reduces postoperative bleeding in coronary artery bypass graft

Efficacy of perioperative systemic tranexamic acid along with topical hemocoagulase in decreasing axillary drain output in breast cancer patients undergoing axillary lymph node dissection: A randomized, double‐blind, placebo‐controlled, superiority trial

Effectiveness And Safety Of Tranexamic Acid In Reducing Blood Loss In Total Knee Arthroplasty: A Meta-Analysis

Effect of intravenous lidocaine on chronic postoperative pain in patients undergoing breast cancer surgery: a prospective, double-blind, randomized, placebo-controlled clinical trial

Desmopressin use in major cardiac surgery is associated with renal impairment: a retrospective single-center analysis

[Experience in Reducing Intraoperative Blood Loss in Radical Retropubic Prostatectomy].

Effect of Acute Normovolemic Hemodilution Combined with Controlled Low Central Venous Pressure on Blood Coagulation Function and Blood Loss in Patients Undergoing Resection of Liver Cancer Operation

Reducing Postsurgical Exudate In Breast Cancer Patients By Using San Huang Decoction To Ameliorate Inflammatory Status: A Prospective Clinical Trial